Table 3.
Clinical characteristics, drug concentrations and genotyping of Plasmodium vivax among patients with recurrences
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age (years) | 22 | 57 | 20 | 60 |
| Gender | Male | Male | Male | Male |
| Weight (kg) | 84.7 | 83 | 70 | 60 |
| Body mass index | 28.40 | 29.76 | 25.40 | 23.73 |
| Past h/o malaria | Yes | No | Yes | No |
| Clinical phenotype of index episode | Non-severe | Non-severe | Non-severe | Non-severe |
| Schizonticidal drug | Chloroquine | Artesunate + Doxycycline | Chloroquine | Chloroquine |
| Regimen of PQ | High | Low | Low | High |
| Actual dose of PQ received (mg/day) | 45.0 | 22.5 | 15.0 | 30.0 |
| Actual dose of PQ received (mg/kg) | 0.53 | 0.27 | 0.21 | 0.50 |
| Time to first recurrence (days) | 105 | 100 | 93 | 80 |
| Clinical phenotype of recurrent episode | Non-severe | Non-severe | Non-severe | Non-severe |
| Schizonticidal drug of recurrence | Chloroquine | Chloroquine | Chloroquine | Chloroquine |
| PQ dose during recurrent episode (mg/day) | 45.0 | 15.0 | 37.5 | 30.0 |
| Drug levels during index episode | ||||
| PQ Level (µg/ml) | 6.518 | 0.240 | 0.159 | NA |
| CPQ Level (µg/ml) | 4.714 | 8.026 | 0.746 | NA |
| Drug levels during recurrence | ||||
| PQ Level (µg/ml) | 0.267 | NA | 0.399 | NA |
| CPQ Level (µg/ml) | 3.873 | NA | 0.536 | NA |
| Amplicon sizes (MS7) | ||||
| Initial infection | 342 | 351 | 351 | 345 |
| Recurrent infection | 342 | 351 | 351 | 345 |
| Amplicon sizes (MS10) | ||||
| Initial infection | 263 | 254 | 290 | 290 |
| Recurrent infection | 263 | 254 | 290 | 290 |
NA not available